IP Verse

Ret Inhibitor For Use In Treating Cancer Having A Ret Alteration

Patent No. EP3773589 (titled "Ret Inhibitor For Use In Treating Cancer Having A Ret Alteration") was filed by Blueprint Medicines on Apr 3, 2019. The application was issued on Nov 1, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
SANDOZJul 12, 2024ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3773589

BLUEPRINT MEDICINES
Application Number
EP19718531A
Filing Date
Apr 3, 2019
Status
Granted And Under Opposition
Sep 29, 2023
Publication Date
Nov 1, 2023
External Links
Slate, Register , Google Patents